Supernus Pharmaceuticals Files 8-K on Financial Condition
Ticker: SUPN · Form: 8-K · Filed: Apr 23, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K for Q1 2025 results, no major news.
AI Summary
On April 23, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition. The filing does not contain specific financial figures or significant events beyond the standard reporting requirement for the period ending April 23, 2025.
Why It Matters
This filing serves as a routine update on Supernus Pharmaceuticals' financial status, providing transparency to investors about the company's operational results.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting results of operations and financial condition without disclosing any new material events or significant financial changes.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- April 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition as of April 23, 2025.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is April 23, 2025.
In which state was Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. was incorporated in Delaware.
What is the address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices?
The address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices is 9715 Key West Ave, Rockville, MD 20850.
Does this 8-K filing disclose any specific new financial results or material events?
Based on the provided text, this 8-K filing is a standard report on Results of Operations and Financial Condition and does not explicitly disclose specific new financial figures or material events beyond the reporting requirement itself.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).